Document is current
Any future updates will be listed below
-
Authors
Lennartz, David Paul
Seikrit, Claudia
Wied, Stephanie
Fitzner, Christina
Eitner, Frank
Hilgers, Ralf-Dieter
Rauen, Thomas
Floege, Jürgen
-
Funding
Funding for this research was provided by:
RWTH Aachen
- License Information
-
More Information
Article History
Received: 6 May 2020
Accepted: 11 August 2020
First Online: 27 August 2020
Compliance with ethical standards
:
: J.F. has received consultant honoraria from Omeros, USA, Retrophin, USA and Calliditas, Sweden. The other authors declare no competing financial interests.
: The STOP-IgAN trial was performed in line with with the principles of the 1964 Declaration of Helsinki and approval was granted by the Ethics Committees at each participating center (, NCT00554502).
: The STOP-IgAN trial was conducted as a multicenter, open label, randomized, controlled study between February 2008 and October 2011 (, NCT00554502). All data presented in this secondary analysis were recorded as detailed in the study protocol []. The STOP-IgAN trial was performed in line with the principles of the 1964 Declaration of Helsinki and approval was granted by the Ethics Committees at each participating center.
: Written informed consent was obtained from all individual participants included in the STOP-IgAN trial prior to trial enrollment. This consent included collection of serum samples.
